Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Hims & Hers Health, Inc. (NYSE: HIMS) reported better-than-expected fourth-quarter financial results and issued strong guidance on Monday.
Hims & Hers Health reported quarterly earnings of 1 cent per share which beat the analyst consensus estimate of losses of 3 cents per share. The company reported quarterly sales of $246.62 million which beat the analyst consensus estimate of $245.82 million by 0.33% and represents a 47.5% increase over sales of $167.2 million from the same period last year, according to data from Benzinga Pro.
“Our outstanding results in 2023 underscore the power of the Hims & Hers brands and superior execution across the organization,” said Andrew Dudum, CEO of Hims & Hers Health. “We are continuing to advance our mission to make the world feel great through the power of better health, which is evident in the significant, consistent and category-leading revenue growth and market share gains we have been delivering. In 2024, we expect to eclipse $1 billion in revenue and deliver our first full year of net income profitability through a continued focus on building personalized and accessible treatments in each of our core specialties.”
Hims & Hers Health sees first-quarter 2024 revenue in the range of $267 million to $272 million, versus the $252.548 million estimate. The company sees fiscal year 2024 revenue of between $1.17 billion and $1.20 billion, versus the $1.099 billion estimate.
Hims & Hers Health shares gained 31.9% to trade at $13.52 on Tuesday.
These analysts made changes to their price targets on Hims & Hers Health after the company reported quarterly results.
- Truist Securities boosted the price target on Hims & Hers Health from $10 to $13. Truist Securities analyst Jailendra Singh maintained a Hold rating.
- Piper Sandler raised the price target on Hims & Hers Health from $9 to $11. Piper Sandler analyst Michael Lavery maintained a Neutral rating.
- Citigroup increased the price target on Hims & Hers Health from $12 to $16. Citigroup analyst Daniel Grosslight maintained a Buy rating.
- Guggenheim raised the price target on Hims & Hers Health from $15 to $17. Guggenheim analyst Jack Wallace maintained a Buy rating.
Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1
Latest Ratings for HIMS
| Mar 2022 | Deutsche Bank | Initiates Coverage On | Hold | |
| Dec 2021 | Citigroup | Maintains | Buy | |
| Dec 2021 | Jefferies | Initiates Coverage On | Hold |
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.